Related Experiment Videos
The sensitivity of head and neck squamous cell carcinomas to tumor necrosis factor-alpha
I Mochimatsu1, M Tsukuda, S Furukawa
1Department of Otorhinolaryngology, Yokoham City University, School of Medicine, Kanagawa, Japan.
Abstract:
Sensitivities to recombinant human tumor necrosis factor-alpha (TNF-alpha) and chemotherapeutic agents (cisplatin, peplomycin, methotrexate) were evaluated in 20 tumor cells of head and neck squamous cell carcinomas, using a dye uptake method. Also, numbers of TNF receptors of these tumor cells were measured by Scatchard plot analysis. There was no relationship between the number of TNF-alpha receptors and the sensitivity to TNF-alpha. Furthermore, there was no correlation between the sensitivity to TNF-alpha and that to chemotherapeutic drugs, nor between the sensitivity to TNF-alpha and the clinical response to chemotherapy including of cisplatin and peplomycin. The sensitivity to TNF-alpha was higher in poorly differentiated carcinomas than in well differentiated ones.
Insights
Tumor necrosis factor-alpha (TNF-alpha) sensitivity in head and neck cancers did not correlate with TNF-alpha receptor numbers or chemotherapy response. Poorly differentiated tumors showed higher TNF-alpha sensitivity.
Area of Science:
- Oncology
- Cancer Biology
- Head and Neck Cancer Research
Background:
- Head and neck squamous cell carcinomas (HNSCC) present diverse responses to therapies.
- Understanding the role of tumor necrosis factor-alpha (TNF-alpha) and its receptors in HNSCC is crucial for targeted treatment strategies.
Purpose of the Study:
- To investigate the relationship between TNF-alpha sensitivity and TNF-alpha receptor expression in HNSCC.
- To evaluate the correlation between TNF-alpha sensitivity and sensitivity to common chemotherapeutic agents (cisplatin, peplomycin, methotrexate).
- To assess the association between TNF-alpha sensitivity and clinical response to chemotherapy in HNSCC patients.
Main Methods:
- Assessed sensitivity of 20 HNSCC tumor samples to recombinant human TNF-alpha and chemotherapeutic agents using a dye uptake method.
- Quantified TNF-alpha receptor numbers on tumor cells via Scatchard plot analysis.
- Correlated in vitro sensitivity data with clinical chemotherapy response.
Main Results:
- No significant relationship was found between the number of TNF-alpha receptors and TNF-alpha sensitivity.
- No correlation observed between TNF-alpha sensitivity and sensitivity to cisplatin, peplomycin, or methotrexate.
- No correlation found between TNF-alpha sensitivity and clinical response to cisplatin and peplomycin.
- Tumor necrosis factor-alpha sensitivity was significantly higher in poorly differentiated HNSCC compared to well-differentiated carcinomas.
Conclusions:
- TNF-alpha receptor expression levels do not predict TNF-alpha sensitivity in HNSCC.
- TNF-alpha sensitivity is not directly correlated with response to common chemotherapy agents or clinical outcomes in HNSCC.
- Tumor differentiation status may influence sensitivity to TNF-alpha in head and neck squamous cell carcinomas.